Syros Pharmaceuticals (SYRS)
(Real Time Quote from BATS)
$1.87 USD
-0.08 (-4.10%)
Updated Sep 23, 2024 03:34 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 1 - 20 ( 225 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Discontinuation Sparks Fears of Read-Through to Phase 3 SELECT-MDS-1: Reit Buy and Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data Rich 3Q/4Q Looks to Cement Tamibarotene''s Place in MDS/AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOLs Reflect On Tamibarotene Attractive Potential in MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A ''SELECT'' MDS/AML Grouping of Potentially Good Data in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dual MDS/AML Data Updates in ?24 Hold Potential Positive Inflection Points; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Triplet Combination Update Is Supportive of Phase 3 Start
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimistic Ahead of SELECT-AML-1 Update in December ?23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Data in 4Q23, With SELECTMDS- 1 Pivotal CR Data in 3Q24; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tamibarotene Continues to Improve its Position in AML and MDS; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Data in 4Q23, Remains The Key Inflection Point; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive SELECT-AML-1 During ASH? 22 Bodes Well for Future Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimistic On SELECT-AML-1?s Data During ASH ?22; Reit. Buy and Raising Our PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Merger with TYME Technologies + PIPE, Recharges Syros? Pipeline; Reit Buy and Lowering our PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 Update - Three Important Derisking Catalysts Expected in 2H2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data Rich 2H22 Should Counterbalance Pipeline De- Prioritizations; Reit Buy and Lower PT to $10 From $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catalysts Speak to Long-Term Growth Potential for Tamibarotene and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Updates - Key Readouts and Study Initiations in 2022, Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z